<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02234141</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-357-1394</org_study_id>
    <secondary_id>2014-002131-34</secondary_id>
    <nct_id>NCT02234141</nct_id>
  </id_info>
  <brief_title>Selonsertib in Adults With Pulmonary Arterial Hypertension</brief_title>
  <acronym>ARROW</acronym>
  <official_title>A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy, safety, and tolerability of three doses of selonsertib
      (GS-4997) to placebo in adults with pulmonary arterial hypertension (PAH). The study will
      consist of a 24-week placebo-controlled treatment period and a long-term selonsertib
      treatment period. Participants completing the 24-week placebo-controlled period will be
      eligible to receive active treatment with selonsertib in the long-term treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pulmonary vascular resistance at Week 24, as measured by right heart catheterization</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in other cardiopulmonary hemodynamic measures</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>Other cardiopulmonary hemodynamic measures will include cardiac index, mean pulmonary artery pressure, mean right atrial pressure, mixed venous oxygen saturation, and right ventricular cardiac power.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in 6-minute walk distance (6MWD)</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in Borg Dyspnea index (BDI) immediately following exercise</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in World Health Organization (WHO) Functional Class</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in N-terminal pro-brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in SF-36 Health Survey physical functioning scale</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in emPHasis-10 questionnaire</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in heart rate recovery after the 6-minute walk test (6MWT)</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening (TTCW) evaluated in the 24-week placebo-controlled treatment period</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in echocardiographic assessments of right ventricular function at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Selonsertib 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive selonsertib 2 mg for 24 weeks and may continue on this dose during the long-term treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selonsertib 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selonsertib 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selonsertib</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Selonsertib 2 mg</arm_group_label>
    <arm_group_label>Selonsertib 6 mg</arm_group_label>
    <arm_group_label>Selonsertib 18 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>GS-4997</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary
             arterial hypertension (HPAH), drug- and toxin-induced PAH, or PAH associated with
             connective tissue disease, HIV infection, or congenital heart defects (repaired
             greater than 1 year prior to Screening)

          -  Meet all of the following hemodynamic criteria by means of a screening right heart
             catheterization (RHC) completed prior to randomization:

               -  Mean pulmonary artery pressure (mPAP) of ≥ 25 mm Hg

               -  Pulmonary vascular resistance (PVR) ≥ 400 dyne•sec/cm^5

               -  Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic
                  pressure (LVEDP) of ≤ 12 mm Hg if PVR ≥ 400 and &lt; 500 dynes•sec/cm^5, or
                  PCWP/LVEDP ≤ 15 mm Hg if PVR ≥ 500 dynes•sec/cm^5

          -  Be able to walk a distance of at least 100 m

          -  Have World Health Organization (WHO) Functional Class II or III symptoms

          -  Meet the following criteria determined by pulmonary function tests completed no more
             than 24 weeks prior to screening, performed with or without bronchodilation:

               -  Forced expiratory volume in one second (FEV1) ≥ 55% of predicted normal

               -  FEV1:forced vital capacity (FVC) ratio ≥ 0.60

          -  Receiving treatment with one or more drugs approved for PAH for ≥ 12 consecutive weeks
             and at stable dose for ≥ 8 consecutive weeks

        Key Exclusion Criteria:

          -  Diagnosis of PAH associated with significant venous or capillary involvement (PCWP &gt;
             15 mm Hg), pulmonary capillary hemangiomatosis, portal hypertension, or unrepaired
             congenital heart defects

          -  Pulmonary hypertension (PH) belonging to groups 2 to 5 of the 2013 NICE classification

          -  Left ventricular ejection fraction (LVEF) ≤ 40% or clinically significant ischemic,
             valvular or constrictive heart disease

          -  Uncontrolled hypertension (≥ 180/110 mm Hg) at Screening

          -  End stage renal disease (receiving peritoneal dialysis, hemodialysis, or status after
             renal transplantation)

          -  Severe liver disease (Child-Pugh Class C, with or without cirrhosis)

        Individuals may be rescreened one additional time with prior notification to and approval
        by the sponsor.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Medical Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Lung Disease Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialist, Ltd</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Clinical and Translational Science (CATS) Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA Biomedical Research Institute Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cardiac and Vascular Center, Anschutz Inpatient Pavillion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary M. Parkes Center // University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martha Morehouse Medical Pavilion</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital, The Lung Centre // Vancouver Coastal Health, Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de caridologie et de pneumologie de Quebee (IUCPQ)</name>
      <address>
        <city>Sainte Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Clinique Universitaire de Pneumologie</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bicetre, Service de Pneumologie-Reanimation Respiratoire</name>
      <address>
        <city>Le Kremlin Bicetre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique-CHRU Lille, Service de cardiologie</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikul Giessen und Marburg GmbH</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik III fur Innere Medizin, Herzzentrum Uniklinik Koln</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fur Innere Medizin II, Universitatsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita &quot;Sapienza&quot;-Azienda Policlinico Umberto 1</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce (12) de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <state>West Dunbartonshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hampstead NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility, Royal Hallamshrie Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <disposition_first_submitted>December 21, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 21, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 23, 2016</disposition_first_posted>
  <last_update_submitted>December 21, 2016</last_update_submitted>
  <last_update_submitted_qc>December 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

